IRVINE, Calif., Nov. 17, 2010 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY™ (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price